Julia Crowther

Julia Crowther

Auto-generated profile, based on publicly available information

Julia Crowther

Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
KHKai Han
Kai Han
JXJin Xu
Jin Xu
FXFang Xie
Fang Xie
JCJulia Crowther
Julia Crowther
JMJames Moon
James Moon
The gut microbiota, predominantly residing in the colon, is a complex ecosystem with a pivotal role in the host immune system. Dysbiosis of the gut microbiota has been associated with various diseases, and there is an urgent need to develop new therapeutics that target the microbiome and restore immune functions. This Brief Review discusses emerging therapeutic strategies that focus on oral delivery systems for modulating the gut microbiome. These strategies include genetic engineering of probiotics, probiotic-biomaterial hybrids, dietary fibers, and oral delivery systems for microbial metabolites, antimicrobial peptides, RNA, and antibiotics. Engineered oral formulations have demonstrated promising outcomes in reshaping the gut microbiome and influencing immune responses in preclinical studies. By leveraging these approaches, the interplay between the gut microbiota and the immune system can be harnessed for the development of novel therapeutics against cancer, autoimmune disorders, and allergies.

3 November 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YCYoung Seok Cho
Young Seok Cho
XZXingwu Zhou
Xingwu Zhou
XSXiaoqi Sun
Xiaoqi Sun
ZWZiye Wan
Ziye Wan
JCJulia Crowther
Julia Crowther
JMJames Moon
James Moon
Toll-like receptor (TLR) agonists, as potent immunostimulatory adjuvants, play a critical role in linking the innate and adaptive immune responses. However, their antitumor effects as cancer immunotherapeutic agents have been limited. Here, we report our finding that manganese ion (Mn 2+ ) potentiates various TLR agonists, leading to robust activation of the TLR pathway and the stimulator of interferon genes (STING) pathway among innate immune cells. In particular, we have observed robust antitumor efficacy after intratumoral administration of a TLR3 agonist and Mn 2+ . To achieve systemic codelivery of TLR3 agonist and Mn 2+ , we have developed a low-molecular-weight poly(inosinic:cytidylic acid)-Mn 2+ coordination lipid nanoparticle (PLCMP). When administered intravenously in tumor-bearing mice, PLCMP successfully accumulated in tumor, induced innate immune activation, generated tumor-specific T cells, and exerted antitumor efficacy in TLR3- and STING-dependent manner without triggering overt toxicity. Moreover, PLCMP in combination with α-PD-1 therapy achieved long-lasting antitumor efficacy in multiple murine tumor models. Furthermore, vaccination with PLCMP carrying TC-1 tumor antigen peptide elicited strong antigen-specific CD8 + T cell responses and remodeled the tumor microenvironment, resulting in robust therapeutic efficacy. Overall, these results show that simultaneous activation of the TLR3 and STING pathways via PLCMP provides a promising strategy for immunotherapy and vaccination against cancer.

10 August 2026 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
KHKai Han
Kai Han
YCYoung Seok Cho
Young Seok Cho
MTMariko Takahashi
Mariko Takahashi
XZXingwu Zhou
Xingwu Zhou
HDHannah E. Dobson
Hannah E. Dobson
JMJames Moon
James Moon
Gut microbial metabolites play crucial roles in regulating systemic immunity, but their mechanisms and limited drug-like properties remain unresolved. Here we report an oral nano-formulation that leverages gut microbial metabolites to modulate T cell metabolism and amplify antitumour immunity. Through an in vitro screening of gut microbial metabolites, we identified 3,4-dihydroxybenzoic acid that improved adoptive T cell therapy and enhanced CD8+ T cell stemness by suppressing glycolysis and regulating the Akt-mTORC1-Myc pathway. To harness the potency of 3,4-dihydroxybenzoic acid for systemic cancer immunotherapy, we engineered a 3,4-dihydroxybenzoic acid prodrug nano-emulsion, significantly increasing its oral absorption and half-life. In multiple murine tumour models, the oral nano-emulsion enhanced the expansion of antigen-specific, stem-like CD8+ T cells, sensitizing tumours to anti-PD-1 blockade and exerting robust antitumour efficacy. By integrating nanotechnology with microbial-metabolite-based immunotherapy, this study establishes a mechanistic link between the gut microbiota and T cell immunity, offering a promising approach for cancer immunotherapy.

10 January 2025 in KONA Powder and Particle Journal
Verified
Journal Article
Open access
PDF file
MRMariana Romero-Gonzalez
Mariana Romero-Gonzalez
JCJulia Crowther
Julia Crowther
MOMani Ordoubadi
Mani Ordoubadi
ABAshlee Brunaugh
Ashlee Brunaugh
Particle engineering broadly refers to the controlled production of drug particles optimized for size, morphology, and structure. It encompasses both destructive (top-down) and constructive (bottom-up) particle formation processes, of which the most used for commercial dry powder inhaler products are milling and spray drying. In both cases, undesirable physicochemical changes may occur because of thermal and mechanical stresses and through interactions with solvents, and can be further potentiated through storage and interaction with atmospheric water. The occurrence and extent of these phenomena are dependent upon the process parameters and the starting material, which necessitates a thorough understanding of these factors to create a stable product with the necessary characteristics for lung deposition. This review covers commonly arising issues in particle engineering and mechanisms of prevention. Topics to be discussed relating to physical changes include (1) the unintended generation of crystalline disorder and amorphous regions in particles; (2) polymorphic transformations; (3) unintended crystallization when amorphization is desired; and (3) triboelectric charging. Topics to be discussed relating to chemical changes include (1) thermal and mechanically activated chemical reactions; and (2) crystalline disorder and chemical reactivity.